ANI has obtained the green light from the Food and Drug Administration for clorazepate dipotassium tablets, which are the generic of Tranxene.
Clorazepate dipotassium tablets, which are used to manage anxiety disorders, have a market value of approximately $25.8 million, according to IQVIA.
[Read more: FDA gives ANI green light for generic Cortrophin Gel]
“We continue to strengthen our base business with new product launches,” said Nikhil Lalwani, president and CEO of ANI. “The imminent launch and commercialization of clorazepate dipotassium tablets is another example of our ongoing commitment to ensuring that patients in need have access to important therapeutics.”
[Read more: ANI names new CEO]